Rosadas, Carolina; Imperial College London London UK
Kidiga, Maureen; Kyoto University Kyoto Japan
Djalo, Fatumata; Imperial College London London UK
Murphy, Edward L; University of California San Francisco California USA
Mouinga-Ondeme, Augustin; Centre Interdisciplinaire de Recherches Médicales de Franceville Unité des Infections Rétrovirales et Pathologies Associées Franceville Gabon
Vermeulen, Marion; The South African National Blood Service (SANBS) Roodeport Gauteng South Africa
Morrell, Louine; Communicable Disease Control Unit Seychelles Hospital Victoria Seychelles
Diop, Saliou ; University Cheikh Anta Diop, and National Blood Transfusion center Dakar Senegal
Gessain A, Ramassamy J-L, Afonso PV, Cassar O. Geographic distribution, clinical epidemiology and genetic diversity of the human oncogenic retrovirus HTLV-1 in Africa, the world's largest endemic area. Front Immunol. 2023;14:1043600.
Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388.
Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Nat Acad Sci USA. 1980;77:7415-7419.
Poiesz BJ, Ruscetti FW, Mier JW, Woods AM, Gallo RC. T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Proc Natl Acad Sci USA. 1980;77:6815-6819.
Afonso PV, Cassar O, Gessain A. Molecular epidemiology, genetic variability and evolution of HTLV-1 with special emphasis on African genotypes. Retrovirology. 2019;16:39.
Katsuya H, Ishitsuka K, Utsunomiya A, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126:2570-2577.
Gessain A, Vernant JC, Maurs L, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985;326:407-410.
Schierhout G, McGregor S, Gessain A, Einsiedel L, Martinello M, Kaldor J. Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infect Dis. 2020;20:133-143.
Vermeulen M, Sykes W, Coleman C, et al. The prevalence of human T-lymphotropic virus type 1 & 2 (HTLV-1/2) in South African blood donors. Vox Sang. 2019;114:451-458.
Cook LB, Fuji S, Hermine O, et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37:677-687.
Cook LB, Phillips AA. How I treat adult T-cell leukemia/lymphoma. Blood. 2021;137:459-470.
Dou F, Tian Z, Yang X, Li J, Wang R, Gao J. Valemetostat: first approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma. Drug Discov Ther. 2022;16:297-299.
Damaj G, Bazarbachi A, Berning P, et al. Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee. Lancet Haematol. 2025;12:e542-e554.
Hlela C, Bittencourt A. Infective dermatitis associated with HTLV-1 mimics common eczemas in children and may be a prelude to severe systemic diseases. Dermatol Clin. 2014;32:237-248.
Gout O, Baulac M, Gessain A, et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med. 1990;322:383-388.
Petruccelli BP, Murray CK, Davis KW, et al. Human T-lymphotropic virus infections in active component service members, U.S. Armed Forces, 2000-2008. MSMR. 2014;21(2):2-4.
Murphy EL. Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and −2): Implications for blood transfusion safety. Transfus Clin Biol. 2016;23:13-19.
Hewitt PE, Davison K, Howell DR, Taylor GP. Human T-lymphotropic virus lookback in NHS Blood and Transplant (England) reveals the efficacy of leukoreduction. Transfusion (Paris). 2013;53:2168-2175.
Kidiga M, Murata M, Grover P, et al. Identification of occult STLV-1 infection in Japanese macaques. J Infect Dis. 2025;232:510-518. doi:10.1093/infdis/jiaf120
Maseko SB, Brammerloo Y, Van Molle I, et al. Identification of small molecule antivirals against HTLV-1 by targeting the hDLG1-Tax-1 protein-protein interaction. Antiviral Res. 2023;217:105675.
Puttemans J, Brammerloo Y, Blibek K, et al. Inhibitors of Tax1-PDZ interactions block HTLV-1 viral transmission by changing EV composition. J Extracell Vesicles. 2025;14:e70137.
